Development of Protein-Like Reference Material for Semiquantitatively Monitoring Visible Proteinaceous Particles in Biopharmaceuticals

References

1. 1.↵
   1. Ratanji K. D.,
   2. Derrick J. P.,
   3. Dearman R. J.,
   4. Kimber I.

   Immunogenicity of Therapeutic Proteins: Influence of Aggregation. J. Immunotoxicol. 2014, 11 (2), 99–109.

   OpenUrlCrossRefPubMedWeb of Science
2. 2.↵
   1. Ahmadi M.,
   2. Bryson C. J.,
   3. Cloake E. A.,
   4. Welch K.,
   5. Filipe V.,
   6. Romeijn S.,
   7. Hawe A.,
   8. Jiskoot W.,
   9. Baker M. P.,
   10. Fogg M. H.

   Small Amounts of Sub-Visible Aggregates Enhance the Immunogenic Potential of Monoclonal Antibody Therapeutics. Pharm. Res. 2015, 32 (4), 1383–1394.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Moussa E. M.,
   2. Panchal J. P.,
   3. Moorthy B. S.,
   4. Blum J. S.,
   5. Joubert M. K.,
   6. Narhi L. O.,
   7. Topp E. M.

   Immunogenicity of Therapeutic Protein Aggregates. J. Pharm. Sci. 2016, 105 (2), 417–430.

   OpenUrl
4. 4.↵
   1. Filipe V.,
   2. Jiskoot W.,
   3. Basmeleh A. H.,
   4. Halim A.,
   5. Schellekens H.,
   6. Brinks V.

   Immunogenicity of Different Stressed IgG Monoclonal Antibody Formulations in Immune Tolerant Transgenic Mice. mAbs 2012, 4 (6), 740–752.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Neubert H.,
   2. Grace C.,
   3. Rumpel K.,
   4. James I.

   Assessing Immunogenicity in the Presence of Excess Protein Therapeutic Using Immunoprecipitation and Quantitative Mass Spectrometry. Anal. Chem. 2008, 80 (18), 6907–6914.

   OpenUrlPubMed
6. 6.↵
   1. Doessegger L.,
   2. Mahler H. C.,
   3. Szczesny P.,
   4. Rockstroh H.,
   5. Kallmeyer G.,
   6. Langenkamp A.,
   7. Herrmann J.,
   8. Famulare J.

   The Potential Clinical Relevance of Visible Particles in Parenteral Drugs. J. Pharm. Sci. 2012, 101 (8), 2635–2644.

   OpenUrlPubMed
7. 7.↵
   1. Bukofzer S.,
   2. Ayres J.,
   3. Chavez A.,
   4. Devera M.,
   5. Miller J.,
   6. Ross D.,
   7. Shabushnig J.,
   8. Vargo S.,
   9. Watson H.,
   10. Watson R.

   Industry Perspective on the Medical Risk of Visible Particles in Injectable Drug Products. PDA J. Pharm. Sci. Technol. 2015, 69 (1), 123–139.

   OpenUrlFREE Full Text
8. 8.↵
   1. Telikepalli S.,
   2. Shinogle H. E.,
   3. Thapa P. S.,
   4. Kim J. H.,
   5. Deshpande M.,
   6. Jawa V.,
   7. Middaugh C. R.,
   8. Narhi L. O.,
   9. Joubert M. K.,
   10. Volkin D. B.

   Physical Characterization and In Vitro Biological Impact of Highly Aggregated Antibodies Separated into Size-Enriched Populations by Fluorescence-Activated Cell Sorting. J. Pharm. Sci. 2015, 104 (5), 1575–1591.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Roberts C. J.

   Protein Aggregation and Its Impact on Product Quality. Curr. Opin. Biotechnol. 2014, 30, 211–217.

   OpenUrl
10. 10.↵
    1. Wuchner K.,
    2. Buchler J.,
    3. Spycher R.,
    4. Dalmonte P.,
    5. Volkin D. B.

    Development of a Microflow Digital Imaging Assay to Characterize Protein Particulates during Storage of a High Concentration IgG1 Monoclonal Antibody Formulation. J. Pharm. Sci. 2010, 99 (8), 3343–3361.

    OpenUrlPubMed
11. 11.↵
    1. Lee K.,
    2. Lankers M.,
    3. Valet O.

    Identification of Particles in Parenteral Drug Raw Materials. PDA J. Pharm. Sci. Technol. 2018, 72 (6), 599–607.

    OpenUrlAbstract/FREE Full Text
12. 12.↵
    1. Wang W.,
    2. Roberts C. J.

    Aggregation of Therapeutic Proteins; Wang W., Roberts C. J., Eds.; John Wiley & Sons, Inc: Hoboken, New Jersey, 2010.
13. 13.↵
    1. Langille S. E.

    Particulate Matter in Injectable Drug Products. PDA J. Pharm. Sci. Technol. 2013, 67 (3), 186–200.

    OpenUrlAbstract/FREE Full Text
14. 14.↵
    Council of Europe, Recommendations on Testing of Particulate Contamination: Visible Particles, Chapter 5.17.2. In European Pharmacopoeia (Ph. Eur.), Council of Europe: Strasbourg, France, 2018.
15. 15.↵
    1. Mathonet S.,
    2. Mahler H. C.,
    3. Esswein S. T.,
    4. Mazaheri M.,
    5. Cash P. W.,
    6. Wuchner K.,
    7. Kallmeyer G.,
    8. Das T. K.,
    9. Finkler C.,
    10. Lennard A.

    A Biopharmaceutical Industry Perspective on the Control of Visible Particles in Biotechnology-Derived Injectable Drug Products. PDA J. Pharm. Sci. Technol. 2016, 70 (4), 392–408.

    OpenUrlAbstract/FREE Full Text
16. 16.↵
    U.S. Pharmacopeial Convention, General Chapter <790> Visible Particulates in Injections. In USP 39–NF 32, USP: Rockville, MD, 2016. [USP 39 NF 32].
17. 17.↵
    Council of Europe, Particulate Contamination: Visible Particles, Chapter 2.9.20. In European Pharmacopoeia (Ph. Eur.), 5th Edition, Council of Europe: Strasbourg, France, 2008.
18. 18.↵
    Ministry of Health, Labour and Welfare of Japan, General Tests, Processes and Apparatus–6.06: Foreign Insoluble Matter Test for Injections. In The Japanese Pharmacopoeia, 17th Edition (English Version), MHLW: Tokyo, 2016.
19. 19.↵
    1. Melchore J. A.

    Sound Practices for Consistent Human Visual Inspection. AAPS PharmSciTech 2011, 12 (1), 215–221.

    OpenUrlPubMed
20. 20.↵
    U.S. Pharmacopeial Convention, General Chapter <1790> Visual Inspection of Injections. In USP 40–NF 35, USP: Rockville, MD, 2017.
21. 21.↵
    Monoclonal antibodies for human use (2031), Pharmeuropa 2010, 22 (1), 49–53.

    OpenUrl
22. 22.↵
    1. Cash P. W.,
    2. Narwal R.,
    3. Levitskaya S. V.,
    4. Krause S.,
    5. Murphy D.,
    6. Mazaheri M.

    Semi-Quantitative Analysis of Inherent Visible Particles for Biopharmaceutical Products. PDA J. Pharm. Sci. Technol. 2016, 70 (2), 134–142.

    OpenUrlAbstract/FREE Full Text
23. 23.↵
    1. Ripple D. C.,
    2. Montgomery C. B.,
    3. Hu Z.

    An Interlaboratory Comparison of Sizing and Counting of Subvisible Particles Mimicking Protein Aggregates. J. Pharm. Sci. 2015, 104 (2), 666–677.

    OpenUrl